Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 25217 results found since Jan 2013.
Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling
CONCLUSION: We demonstrated that SOX2/Notch signaling was responsible for Enzalutamide resistance in CRPC. Targeting SOX2/Notch signaling might represent a new choice for the treatment and therapy of CRPC.PMID:37716921 | DOI:10.1007/s11033-023-08757-y
Source: Mol Biol Cell - September 16, 2023 Category: Molecular Biology Authors: Zhongbo Du Xiaobin Chen Pingyu Zhu Qi Lv Jun Yong Junqing Gu Source Type: research
Reciprocal negative feedback regulation of ATF6 α and PTEN promotes prostate cancer progression
Cell Mol Life Sci. 2023 Sep 16;80(10):292. doi: 10.1007/s00018-023-04940-3.ABSTRACTPhosphatase and tensin homolog (PTEN) loss tightly correlates with prostate cancer (PCa) progression and metastasis. Inactivation of PTEN leads to abnormal activation of PI3K/AKT pathway. However, results from clinical trials with AKT inhibitors in PCa have been largely disappointing. Identification of novel regulators of PTEN in PTEN-dysfunctional PCa is urgently needed. Here we demonstrated that the expression level of PTEN is inversely correlated with the signature score of unfolded protein response (UPR) in PCa. Importantly, PTEN suppres...
Source: Cellular and Molecular Life Sciences : CMLS - September 16, 2023 Category: Cytology Authors: Tingting Feng Ru Zhao Hanwen Zhang Feifei Sun Jing Hu Meng Wang Mei Qi Ling Liu Lin Gao Yabo Xiao Junhui Zhen Weiwen Chen Lin Wang Bo Han Source Type: research
Ki67 and prostate specific antigen are prognostic in metastatic hormone na ïve prostate cancer
CONCLUSION: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.PMID:37713321 | DOI:10.1080/0284186X.2023.2254480
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Vasiliki Spyratou Eva Freyhult Anders Bergh Camilla Thellenberg-Karlsson Pernilla Wikstr öm Karin Wel én Andreas Josefsson Source Type: research
A Case of Metastatic Papillary Thyroid Carcinoma in Neck Lymph Nodes Without Primary Tumor in Thyroid Gland
We report the case of a 63-year-old male who had a left neck level II palpable mass. A left cervical mass had previously undergone 2 central needle biopsies, but only atypical cells had been identified. His prior medical history included surgical treatment for prostate cancer 11 years ago. There was no suspicious primary tumor in the endoscopic examination. After the excisional biopsy, the pathologic finding was metastatic papillary carcinoma from the thyroid, and there were no aberrant findings in the thyroid sonography. The patient underwent a complete thyroidectomy, bilateral central neck dissection (CND), and left leve...
Source: Ear, Nose and Throat Journal - September 15, 2023 Category: ENT & OMF Authors: Sung Ha Jung Joo Hyun Park Junyoung Kim Nayeon Choi Source Type: research
Erratum: Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390166CX1. doi: 10.1200/EDBK_390166CX1.NO ABSTRACTPMID:37713646 | DOI:10.1200/EDBK_390166CX1
Source: Clinical Prostate Cancer - September 15, 2023 Category: Cancer & Oncology Source Type: research
Prehabilitative versus rehabilitative exercise in prostate cancer patients undergoing prostatectomy
CONCLUSION: Pre-surgical exercise enhanced strength and function, protecting against post-surgery declines. Although exercise post-surgery is beneficial for recouping strength and function, where possible men undergoing prostatectomy are encouraged to exercise pre-surgery.TRIAL REGISTRATION: ACTRN12617001115325 registered 31 July 2017.PMID:37712960 | DOI:10.1007/s00432-023-05409-3
Source: Clinical Prostate Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Favil Singh Robert U Newton Dennis R Taaffe Pedro Lopez Jeff Thavaseelan Matthew Brown Elayne Ooi Kazunori Nosaka Dickon Hayne Daniel A Galv ão Source Type: research
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
CONCLUSION: Relugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.TRIAL REGISTRATION: Clinical Trial ID NCT03085095.PRIOR PRESENTATION: Data presented at 15th Annual Genitourinary Cancers Symposium; February 17-19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found at https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101 .PMID:37713020 | DOI:10.1007/s12325-023-02634-7
Source: Adv Data - September 15, 2023 Category: Epidemiology Authors: Neal D Shore Bryan A Mehlhaff Michael S Cookson Daniel R Saltzstein Ronald Tutrone Bruce Brown Sophia Lu Mark Fallick Sarah Hanson Fred Saad Source Type: research
Network pharmacology and molecular docking to explore the mechanism of Sheng Xue Bao mixture against iron deficiency anemia
Medicine (Baltimore). 2023 Sep 15;102(37):e35012. doi: 10.1097/MD.0000000000035012.ABSTRACTBased on network pharmacology and molecular docking, we investigated the mechanism of action of Sheng Xue Bao mixture (SXBM) in treating iron deficiency anemia (IDA). We screened the HERB and traditional Chinese medicine systems pharmacology database and analysis platform databases to identify the active ingredients and targets of SXBM. The targets associated with "iron deficiency anemia" were collected from GeneCards, TTD, and OMIM databases. A component-target interaction network was constructed using Cytoscape 3.8.2. The protein-p...
Source: Atherosclerosis - September 15, 2023 Category: Cardiology Authors: Yun Wang Huang Qinqin Haixia Wang Hongxu Zhang Xinhua Zhang Weiguo Liu Zhenhua Xiang Yuming Gu Source Type: research
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting.FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus a...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Fred Saad Noel W Clarke Mototsugu Oya Neal Shore Giuseppe Procopio Jo ão Daniel Guedes Cagatay Arslan Niven Mehra Francis Parnis Emma Brown Friederike Schl ürmann Jae Young Joung Mikio Sugimoto Oliver Sartor Yu-Zhen Liu Christian Poehlein Laura Barker P Source Type: research
Erratum: Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390166CX1. doi: 10.1200/EDBK_390166CX1.NO ABSTRACTPMID:37713646 | DOI:10.1200/EDBK_390166CX1
Source: Clinical Prostate Cancer - September 15, 2023 Category: Cancer & Oncology Source Type: research
Prehabilitative versus rehabilitative exercise in prostate cancer patients undergoing prostatectomy
CONCLUSION: Pre-surgical exercise enhanced strength and function, protecting against post-surgery declines. Although exercise post-surgery is beneficial for recouping strength and function, where possible men undergoing prostatectomy are encouraged to exercise pre-surgery.TRIAL REGISTRATION: ACTRN12617001115325 registered 31 July 2017.PMID:37712960 | DOI:10.1007/s00432-023-05409-3
Source: Clinical Prostate Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Favil Singh Robert U Newton Dennis R Taaffe Pedro Lopez Jeff Thavaseelan Matthew Brown Elayne Ooi Kazunori Nosaka Dickon Hayne Daniel A Galv ão Source Type: research
Ki67 and prostate specific antigen are prognostic in metastatic hormone na ïve prostate cancer
CONCLUSION: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.PMID:37713321 | DOI:10.1080/0284186X.2023.2254480
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Vasiliki Spyratou Eva Freyhult Anders Bergh Camilla Thellenberg-Karlsson Pernilla Wikstr öm Karin Wel én Andreas Josefsson Source Type: research
LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients
CONCLUSIONS: Subclassification of IR prostate cancer into FIR and UIR subcategories appears mandatory. For FIR patients, outcomes after BT monotherapy were acceptable. However, clinical failure after 125J-LDR-BT in UIR patients was notably increased, suggesting that BT monotherapy was less successful in this risk group. In contrast, the outcome in UIR patients after CRT was excellent.PMID:37714724 | DOI:10.1016/j.urolonc.2023.08.007
Source: Urologic Oncology - September 15, 2023 Category: Urology & Nephrology Authors: Andreas Boehle Dorothea Zywietz Irina Robrahn-Nitschke Achim Lusch Inke R K önig Source Type: research
A systematic planning method to spare the rectal wall in radiotherapy of prostate cancer
Acta Oncol. 2023 Sep 15:1-4. doi: 10.1080/0284186X.2023.2252587. Online ahead of print.NO ABSTRACTPMID:37712583 | DOI:10.1080/0284186X.2023.2252587
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Kirsten Jakobsen Laura Patricia Kaplan Romain Marsguerra Marko Bebek Kenneth Francis Hoffland Eva Samsoee Hinsby Source Type: research
